Seclidemstat + Azacitidine combination (MDS/CMML)

Current understanding

Seclidemstat is a reversible LSD1/KDM1A inhibitor being evaluated in combination with the hypomethylating agent azacitidine in a phase I/II trial for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial seeks to define optimal dosing and early efficacy signals, extending the LSD1-inhibitor + HMA mechanistic rationale (already explored with iadademstat + ASTX727) into the MDS/CMML space. Evidence to date is trial-early with no published outcome data.

Evidence log

• 2026-05-29 — Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia: cross-connection with azacitidine-lenalidomide-vorinostat-mds-cmml: Both combine azacitidine with an epigenetic modifier (vorinostat HDAC inhibitor vs. seclidemstat LSD1 inhibitor) in higher-risk MDS/CMML, offering comparative evidence on epigenetic-add-on strategies. (novelty: 3)
• 2026-04-02 — Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: cross-connection with iadademstat-lsd1-inhibitor: Both seclidemstat and iadademstat are LSD1/KDM1A inhibitors being combined with hypomethylating agents (azacitidine and decitabine/ASTX727 respectively) in myeloid neoplasms — parallel clinical strategies. (novelty: 3)

Open questions

Related